Jefferies analyst Thomas Wei reiterated a Buy rating and $20 price target on Amarin Corporation (NASDAQ: AMRN) following FDA briefing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE